{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:12:17Z","timestamp":1789690337499,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.radonc.2023.109633","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T21:42:37Z","timestamp":1679521357000},"page":"109633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Radiotherapy opens the blood\u2013brain barrier and synergizes with anlotinib in treating glioblastoma"],"prefix":"10.1016","volume":"183","author":[{"given":"Pei-Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Zhen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Jie","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109633_b0005","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2023.109633_b0010","doi-asserted-by":"crossref","unstructured":"Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14:v1-49. doi:10.1093\/neuonc\/nos218","DOI":"10.1093\/neuonc\/nos218"},{"key":"10.1016\/j.radonc.2023.109633_b0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.radonc.2023.109633_b0030","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","article-title":"Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway","volume":"503","author":"He","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.radonc.2023.109633_b0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.32180","article-title":"Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2023.109633_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.23986","article-title":"Combination of anlotinib and gemcitabine promotes the G0 \/ G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro","volume":"35","author":"Fan","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.radonc.2023.109633_b0045","doi-asserted-by":"crossref","unstructured":"Jin Z, Lu Y, Wu X, et al. The cross-talk between tumor cells and activated fibroblasts mediated by lactate\/BDNF\/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer. Redox Biol. 2021;Oct:102076. doi:10.1016\/j.redox.2021.102076.","DOI":"10.1016\/j.redox.2021.102076"},{"key":"10.1016\/j.radonc.2023.109633_b0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","article-title":"Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells","volume":"38","author":"Liang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109633_b0055","doi-asserted-by":"crossref","unstructured":"Jiang S, Liang H, Liu Z, et al. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Oncologist. 2020;25:e870-e874. doi:10.1634\/theoncologist.2019-0838.","DOI":"10.1634\/theoncologist.2019-0838"},{"key":"10.1016\/j.radonc.2023.109633_b0060","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"Gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hamou","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109633_b0065","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.radonc.2023.109633_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.radonc.2023.109633_b0075","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.3390\/cancers7040897","article-title":"Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy","volume":"7","author":"Barbuti","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109633_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108118","article-title":"The role of the STAT3 signaling transduction pathways in radioresistance","volume":"234","author":"Shih","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.radonc.2023.109633_b0085","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1038\/s41388-018-0340-y","article-title":"Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide","volume":"37","author":"Lu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2023.109633_b0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nyas.14787","article-title":"Modifying the blood-brain barrier by targeting claudin-5: Safety and risks","volume":"1514","author":"Wakayama","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.radonc.2023.109633_b0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12987-019-0123-z","article-title":"Claudin-5: gatekeeper of neurological function","volume":"16","author":"Greene","year":"2019","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.radonc.2023.109633_b0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.radonc.2023.109633_b0105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109633_b0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109633_b0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","author":"Reardon","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2023.109633_b0120","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109633_b0125","first-page":"1","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long- term survival in mice with intracranial gliomas","volume":"23","author":"Zeng","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109633_b0130","first-page":"1","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma the checkmate 143 phase 3 randomized clinical trial","volume":"5450","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0135","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF01411440","article-title":"Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats","volume":"136","author":"Nakata","year":"1995","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.radonc.2023.109633_b0145","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2005.07.144","article-title":"Use of magnetic resonance imaging to assess blood-brain\/blood-glioma barrier opening during conformal radiotherapy","volume":"23","author":"Cao","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0150","article-title":"Influence of radiation on the blood-brain barrier and optimum time of chemotherapy","volume":"16","author":"Qin","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109633_b0155","doi-asserted-by":"crossref","first-page":"e112397","DOI":"10.1371\/journal.pone.0112397","article-title":"Low dose cranial irradiation-induced cerebrovascular damage is reversible in mice","volume":"9","author":"S\u00e1ndor","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2023.109633_b0160","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1541-7786.MCR-07-2180","article-title":"Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas","volume":"6","author":"Brantley","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.radonc.2023.109633_b0165","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s12032-014-0924-5","article-title":"STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma","volume":"31","author":"Lin","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0170","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","article-title":"STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression","volume":"11","author":"Kohsaka","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.radonc.2023.109633_b0175","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2023.109633_b0180","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1073\/pnas.1321014111","article-title":"In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift","volume":"111","author":"Halliday","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.radonc.2023.109633_b0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/ERC-17-0558","article-title":"Antitumor effects of anlotinib in thyroid cancer","volume":"26","author":"Ruan","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.radonc.2023.109633_b0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.radonc.2023.109633_b0195","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2174\/1871520621666210112113852","article-title":"Anlotinib overcomes multiple drug resistant of the colorectal cancer cells via inactivating PI3K\/AKT pathway","volume":"21","author":"Lan","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.radonc.2023.109633_b0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2023.109633_b0205","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2007.12.7878","article-title":"Hypoxic radiosensitization: adored and ignored","volume":"25","author":"Overgaard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0210","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2217\/fon.10.123","article-title":"Improving the radiosensitivity of radioresistant and hypoxic glioblastoma","volume":"6","author":"Sheehan","year":"2010","journal-title":"Futur Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0215","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.freeradbiomed.2012.06.009","article-title":"NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme","volume":"53","author":"Hsieh","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.radonc.2023.109633_b0220","doi-asserted-by":"crossref","unstructured":"Ee MACMCG, Amner JBLH, Illiams REFW, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;76(5):1537-1545. doi:10.1016\/j.ijrobp.2009.12.010","DOI":"10.1016\/j.ijrobp.2009.12.010"},{"key":"10.1016\/j.radonc.2023.109633_b0225","doi-asserted-by":"crossref","unstructured":"Lu J, Zhong H, Chu T, et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy. Eur Respir J. 2019;53:1801562. doi:10.1183\/13993003.01562-2018","DOI":"10.1183\/13993003.01562-2018"},{"key":"10.1016\/j.radonc.2023.109633_b0230","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3389\/fonc.2020.00995","article-title":"Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma","volume":"10","author":"Shi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.109633_b0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery","volume":"56","author":"Di","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.radonc.2023.109633_b0255","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/aps.2017.199","article-title":"Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species","volume":"39","author":"Zhong","year":"2018","journal-title":"Acta Pharmacol Sin"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:28:45Z","timestamp":1759123725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023001718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":47,"alternative-id":["S0167814023001718"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109633","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy opens the blood\u2013brain barrier and synergizes with anlotinib in treating glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109633"}}